IN DEPTH VDRM DD w/ALL (reposting for newbies)
apologies if you read before, just doing my part to keep all new investors informed...
1- back in 2.25.2014 philips manufactured there last fda approval of tetrastem, its a 3 year shelf life as im able to see
2 - in 5.28.2014 VDRM started to manufacture there first fda approval of tetrastem, same 3 year shelf life
3 - now heres where it make huge sense in 3.2014 VDRM gets the rights to manufacture tetrastem from phlips, but not until 6.2014 do they get the exclusive rights....1 month after they start there first manufacture of tetrastem
4 - the 3 - 6 - 9 month studies kick in in a huge way, and now VDRM as of 1.2017 manufactures 500,000 bottles for sale,
...basically they took what worked expanded on it and said this is huger than we thought
5 - 12.2016 VDRM files for uopdated Viabecline patent - which is purely application - so that means anyone, anywhere, anytime they use tetrastem which they have to get from VDRM and apply it , VDRM gets a royalty on it, remember the exclusive deal with philips is philips get a few bucks everytime a bottle is sold, so there covered, and now VDRM gets play n 2 directions - hence pure play on licensing and manufacturing and application
6 - back in 2015 rumors started that both PFE and MRK and Endo pharma were looking at VDRM - obviously theyre pissed phillips signed a deal with VDRM and wanted very much to make sure they could get it away from them - well it didnt work as VDRM raised money has now paid for 500,000 bottles and is global outside of the USA and taking off
7 - 2.2017 Dr Otiko to write a paper on diabetic ulcers showing massive results - which means all roads of tetrastem and viabecline lead to VDRM all royalties all future of applications
articles of inetrest ( get them off the web )
1 - from a 2.2011 study reposted in 1.2017 paraplegic uses tetrastem with stem cells and walks again ( philips put the article out , but VDRM gets the future usage from exclusivity )
2 - 3.2015 onychmycosis article
3 - 11.2016 viabecline article
4 - 12.2016 diabetic ulcers study vdrm issued
5 - 12.2016 viabecline patent applied for
6 - 1.2017 vdrm 500,000 bottles manufactured for 2017 grossing 62-65M in sales
so what we have here friends is
tetrastem is philips that gave exclusive rights to vdrm - and tetratsem is an ointment
viabecline is vdrm which is a delivery of tetrastem - whcih can take any oral as well and apply to ointment application
now what we dont see but is obvious is PFE is all about viagra, now imagine a lotion for f on f , not just a pill, and youve opened a huge market in the world away of same sex...mrk is all about diabetes and with application wise they want in too, add in JNJ which bandaids work and graduate to a 1000% increase in healing and they want in too...
VDRM holds alot of these players destiny - so what your seeing was an attempt to hold them back - but they failed and now they have to embrace a license deal with VDRM ahead of 500,000 hitting the cali market by Q2 2017...
add in trump cutting costs in obamacare and vdrm product is 85% cheaper than what was out there with weak results - and the fda will obviously approve them - as theyve been in the queue for a while now and are coming to the fast track probably ahead of the 500,000 launch
so the pieces are coming together - Dr Otiko knows exactly what hes doing and thats why stock is tight - us position players are holding hard - and there in less and less to shake from the tree
this is just part of the research - but im sure we will be uplisted soon enough - and remember the last PFE was a 3.5B buyout and it was a 1 product company with 1 application, here its a 15 - 23B a year market with numerous applications, and VDRM owns both the product and the application
that is what we call a licensing play...
appreciate each market and research each company that presently controls each market PFE JNJ LLY MNKD BGEN AMGN and that VDRM is a pure play on licensing and patents which is brilliant in its own and is lead by people that understand this and appreciate so by controlling 75% of the outstanding stock here
lets break it down just a few sectors and make it a working model for all to add on to so the board is kept knowledge based for all
PFE Viagra is a category killer but it is a pill - and a pill is a introduction internally to the blood stream which out of fear a great portion of the population will just not take, now factor in a female Viagra alternative that is topical and replace the male Viagra with the same topical and its obvious that PFE will be forced to enter some sort of licensing agreement to hold onto there market share and as well look to capitalize on the female market as well ( m on f , and f on f ) there are those that will only use topical not internal
MRK, LLY and MNKD are the diabetic market and its huge - toenail fungal market - now add on a turnaround solution they have been needing for years, to treat at home foot infections ( home care largest market globally ) and that market alone is extraordinary with multiple companies all vying to be the dominant player and VDRM having the solution to license
JNJ marketplace is wounds - the band , now graduate it to the ability to speed the process up say 10 fold to heal any scrapes scratched wounds and to hold there market-share JNJ will be forced to enter some sort of licensing deal just to hold the line or risk crippling there empire quite easily
MRK and JNJ baldness market is in a level all itself, as its a do it yourself world we live in - add a just for men/ ladies crowd solution to expand into the baldness market and make that a CVS Walgreen's etc play for direct access more licensing
without even touching on the other markets there is exceptional growth here ( see my numbers post above that breaks the numbers down for all to see )
This does not include Viabecline -
Lead Product TetraStem
World’s strongest broad spectrum tetracycline-based topical antibiotic with proven results. Used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries.
Very low water content and optimum (low) viscosity. Uses both a chemical AND physical kill mechanism which is advantageous over traditional antibiotics which use only a chemical kill mechanism and has a better resistance profile.
Potential Markets
ViaDerma is developing products in many fields of use, including:
Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $3.02 billion/year
Psoriasis- $7.3 billion/year
Eczema- $2.5 billion/year
Other potential markets include burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. Innovative, patent pending dual carrier transdermal technology which can transform oral medication into topical products. Ability to enable active ingredients with a rapid transport direct to the site of action.
Ability to be used in any field including Sports Nutrition Supplements, Cosmetics, First Aid Products, Wound Care, and Skin Diseases like Acne, Eczema, and Psoriasis. Dual carrier liquid which can possess life enhancing technology with up to four year shelf-life. Facilitates transfer of chemicals through the stratum corneum with a diffusion constant 10,000x higher. Strong Advanced Biological Coverage (ABC) which has higher concentrations, faster penetration and is more effective than conventional antibiotics. ABC produces desirable results in ~24 hours or less compared to 5-7 days. It kills all harmful gram-positive and gram-negative bacteria that have been available for testing.
